LYMPHOMAS

The FDA designates soficabtagene geleucel as a breakthrough therapy, highlighting its potential in treating relapsed T cell leukemia and lymphoma.

Early findings from the QUILT-106 trial reveal promising outcomes for CD19 CAR-NK cell therapy combined with rituximab in treating Waldenstrom lymphoma.

Epcoritamab shows promising results in improving progression-free survival for patients with relapsed/refractory DLBCL, paving the way for future therapies.

Nivolumab plus AVD shows significant improvement in progression-free survival for advanced Hodgkin lymphoma, establishing it as a preferred treatment option.

Spatial transcriptome sequencing uncovers distinct tumor microenvironment subtypes in angioimmunoblastic T-cell lymphoma, enhancing patient stratification and immunotherapy strategies.

ZUMA-14 trial reveals promising efficacy and safety of axi-cel and rituximab combination therapy for refractory large B-cell lymphoma patients.

The FDA denies accelerated approval for tabelecleucel, highlighting ongoing challenges in treating EBV-positive posttransplant lymphoproliferative disease.

A phase 2 study reveals that combining brentuximab vedotin with gemcitabine shows promising efficacy and safety for relapsed peripheral T-cell lymphoma patients.

Denileukin diftitox transforms CTCL treatment by targeting malignant T cells, offering hope for patients with limited options and severe symptoms.

Patients with Waldenström macroglobulinemia experience comparable outcomes when switching from ibrutinib to zanubrutinib, with improved safety profiles.

A phase 3 study shows tafasitamab combined with lenalidomide and R-CHOP significantly improves outcomes for untreated DLBCL patients.

A groundbreaking study reveals that ultrasensitive ctDNA assays significantly enhance prognosis for large B-cell lymphoma, outperforming traditional PET assessments.

FDA approves mosunetuzumab-axgb for quick subcutaneous treatment of relapsed follicular lymphoma, enhancing patient care and reducing clinic time.

Pirtobrutinib shows significant efficacy and safety in treating relapsed/refractory follicular lymphoma, with promising response rates and durable outcomes.

Duvelisib is now a recommended treatment for cutaneous T-cell lymphoma, highlighting its evolving role in oncology amidst safety concerns.

Emerging evidence of the benefit of antibody-drug conjugates in diffuse large B-cell lymphoma continues to make a strong case for the agents to be used in earlier lines of therapy.

Miguel-Angel Perales, MD, spoke with Targeted Oncology® about the problems the CAR T Vision group has identified and the key short-term and long-term steps being taken to expand the accessibility of CAR T-cell therapy.

The FDA reviews nivolumab with chemotherapy as a potential new frontline treatment for advanced classical Hodgkin lymphoma, promising improved outcomes.

A recent study reveals critical insights on disease progression and survival rates in patients with relapsed/refractory large B-cell lymphoma treated with bispecific antibodies.

FDA and EMA approve AVC-203, a groundbreaking CAR-T therapy targeting B-cell malignancies, promising enhanced safety and scalability for patients.

A 6-month complete response predicts improved long-term survival in high-risk large B-cell lymphoma patients treated with axicabtagene ciloleucel.

Dexamethasone prophylaxis significantly reduces severe neurotoxicity in LBCL patients receiving axi-cel, enhancing safety without compromising efficacy.

Sonrotoclax shows promising efficacy and tolerability in treating relapsed mantle cell lymphoma, with ongoing trials to confirm its potential.

Circulating tumor DNA (ctDNA) emerges as a crucial prognostic tool for lymphoma, enhancing event-free survival predictions and treatment response insights.

A novel treatment regimen for high-risk mantle cell lymphoma shows impressive response rates and minimal residual disease in early trial results.